左炔诺孕酮宫内节育系统对子宫腺肌病患者CA125值影响的临床研究

Clinical Research on Levonorgestrel Intrauterine System in the CA125 for Adenomyosis Patients

目的研究左炔诺孕酮宫内节育系统(曼月乐节育环)对子宫腺肌病患者的影响。方法临床纳入180例我院2014年8月—2016年8月收治的子宫腺肌病患者作为研究对象。按随机排列表法分为两组各90例。其中90例患者口服米非司酮治疗作为对照组,另90例患者放置左炔诺孕酮宫内节育系统治疗作为观察组。观察两组患者治疗前后子宫体积、疼痛情况、月经量、CA125水平以及性生活质量等。结果治疗前两组患者子宫体积、疼痛情况、月经量以及CA125水平对比差异无统计学意义,P>0.05;治疗后观察组子宫体积和月经量少于对照组,疼痛情况及CA125水平低于对照组,P<0.05。治疗前两组患者性生活质量评分差异无统计学意义,P>0.05;治疗后观察组患者性生活质量评分均高于对照组,P<0.05。结论曼月乐节育环治疗子宫腺肌病患者可有效缩小患者子宫,改善月经情况,提高性生活质量,安全有效。

Objective To analyze the clinical effect of Mirena IUD （levonorgestrel intrauterine system） in adenomyosis patients. Methods 180 adenomyosis patients treated from August 2014 to August 2016 in our hospital were selected. The subjects were randomly divided into two groups, 90 cases in each group. The control group orally took Mifepristone, the observation group took the Mirena IUD. Before and after treatment, the uterine volume, pain degree, menstrual blood volume, CA125 value and sexual life quality for two groups were observed. Results Before treatment, the uterine volume, pain degree, menstrual blood volume and CA125 value for two groups was not significantly different （P 〉 0.05）. After treatment,the uterine volume and menstrual blood volume for observation group was significantly smaller than control group, the pain degree and CA125 value for observation group was significantly smaller than control group （P 〈 0.05）. Before treatment, the sexual life quality for two groups was not significantly different （P 〉 0.05）. After treatment, the sexual life quality for observation group was significantly higher than control group （P 〈 0.05）. Conclusion For adenomyosis patients, the Mirena IUD can effectively reduce the uterine volume and menstrual blood volume, improve the sexual life quality and clinical safety.